AM-251

AM-251 is a drug that acts as a selective antagonist at the cannabinoid receptor CB1, and is used in scientific research. It is structurally related to the more well-known compound SR141716A, which is approximately equivalent in potency, but AM-251 is slightly more selective for CB1, versus the CB2 subtype, with a Ki of 7.49nM at CB1 vs 403nM at CB2.

Pharmacology

AM-251 is a selective antagonist at the cannabinoid receptor CB1. It is used in scientific research to explore the role of the endocannabinoid system in the body. The compound is structurally related to SR141716A, another cannabinoid receptor antagonist. However, AM-251 is slightly more selective for the CB1 receptor subtype, with a Ki of 7.49nM at CB1 and 403nM at CB2.

Chemistry

AM-251 is a derivative of 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide. It is a white crystalline solid that is soluble in organic solvents.

Uses

AM-251 is primarily used in scientific research. It is used to study the role of the endocannabinoid system in various physiological processes, including pain sensation, mood regulation, and appetite control. It is also used to investigate the potential therapeutic applications of CB1 receptor antagonists.

See also

• Cannabinoid receptor
• CB1 receptor
• CB2 receptor
• SR141716A

References

AM-251 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia